MX2021013711A - Acido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin -3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilico para su uso en pacientes con cancer de mama metastasico o avanzado. - Google Patents

Acido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin -3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilico para su uso en pacientes con cancer de mama metastasico o avanzado.

Info

Publication number
MX2021013711A
MX2021013711A MX2021013711A MX2021013711A MX2021013711A MX 2021013711 A MX2021013711 A MX 2021013711A MX 2021013711 A MX2021013711 A MX 2021013711A MX 2021013711 A MX2021013711 A MX 2021013711A MX 2021013711 A MX2021013711 A MX 2021013711A
Authority
MX
Mexico
Prior art keywords
annulene
oxyphenyl
fluoropropyl
pyrrolidin
dichlorophenyl
Prior art date
Application number
MX2021013711A
Other languages
English (en)
Spanish (es)
Inventor
Sandrine Anneheim-Herbelin
Sylvaine Cartot-Cotton
Marina Celanovic
Patrick Cohen
Alice Gosselin
Gautier Paux
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2021013711A publication Critical patent/MX2021013711A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2021013711A 2019-05-09 2020-05-07 Acido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin -3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilico para su uso en pacientes con cancer de mama metastasico o avanzado. MX2021013711A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19305593 2019-05-09
EP19305679 2019-05-28
US201962945311P 2019-12-09 2019-12-09
PCT/EP2020/062743 WO2020225375A1 (en) 2019-05-09 2020-05-07 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid for use in metastatic or advanced breast cancer patients

Publications (1)

Publication Number Publication Date
MX2021013711A true MX2021013711A (es) 2021-12-10

Family

ID=70681807

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013711A MX2021013711A (es) 2019-05-09 2020-05-07 Acido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin -3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilico para su uso en pacientes con cancer de mama metastasico o avanzado.

Country Status (13)

Country Link
US (2) US20200352905A1 (https=)
EP (1) EP3965758A1 (https=)
JP (1) JP2022531898A (https=)
KR (1) KR20220006553A (https=)
CN (1) CN114173776A (https=)
AU (1) AU2020268762A1 (https=)
BR (1) BR112021022216A2 (https=)
CA (1) CA3146346A1 (https=)
IL (1) IL287805A (https=)
MX (1) MX2021013711A (https=)
SG (1) SG11202111979SA (https=)
TW (1) TW202110434A (https=)
WO (1) WO2020225375A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7413363B2 (ja) 2018-09-07 2024-01-15 サノフイ メチル６－（２，４－ジクロロフェニル）－５－［４－［（３ｓ）－１－（３－フルオロプロピル）ピロリジン－３－イル］オキシフェニル］－８，９－ジヒドロ－７ｈ－ベンゾ［７］アヌレン－２－カルボキシレートの調製方法
WO2021063967A1 (en) 2019-10-01 2021-04-08 Sanofi Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
KR20220113695A (ko) 2019-12-09 2022-08-16 사노피 7h-벤조[7]아눌렌-2-카르복실산 유도체의 결정질 형태
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
WO2022084280A1 (en) 2020-10-19 2022-04-28 Sanofi Substituted 6,7-dihydro-5h-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof
EP4247363A1 (en) * 2020-11-23 2023-09-27 Sanofi Combination comprising abemaciclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
TWI837605B (zh) * 2021-03-09 2024-04-01 美商美國禮來大藥廠 使用serd組合給藥方案治療癌症之方法
CN117042771A (zh) * 2021-03-09 2023-11-10 伊莱利利公司 使用serd给药方案的组合治疗癌症的方法
TW202400136A (zh) * 2022-03-13 2024-01-01 法商賽諾菲公司 以安森司群(amcenestrant)治療乳癌
TW202543650A (zh) 2024-03-08 2025-11-16 美商海爾達醫療運營公司 異雙官能化合物及其在治療疾病中之用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19833786A1 (de) * 1998-07-18 2000-01-20 Schering Ag Benzocycloheptene, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
WO2015082990A1 (en) * 2013-12-06 2015-06-11 Seragon Pharmaceuticals, Inc. Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
JP7019422B2 (ja) * 2015-04-29 2022-02-15 ラジウス ファーマシューティカルズ，インコーポレイテッド 癌を治療するための方法
SMT202300018T1 (it) * 2015-12-09 2023-03-17 Univ Illinois Downregolatori del recettore degli estrogeni a base di benzotiofene
LT3416962T (lt) * 2016-02-15 2021-07-12 Sanofi 6,7-dihidro-5h-benzo[7]anuleno dariniai kaip estrogenų recepptoriaus moduliatoriai
EP3434272A1 (en) * 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid

Also Published As

Publication number Publication date
KR20220006553A (ko) 2022-01-17
IL287805A (en) 2022-01-01
US20200352905A1 (en) 2020-11-12
EP3965758A1 (en) 2022-03-16
JP2022531898A (ja) 2022-07-12
AU2020268762A1 (en) 2021-12-02
WO2020225375A1 (en) 2020-11-12
CA3146346A1 (en) 2020-11-12
TW202110434A (zh) 2021-03-16
US20240091194A1 (en) 2024-03-21
SG11202111979SA (en) 2021-11-29
BR112021022216A2 (pt) 2021-12-28
CN114173776A (zh) 2022-03-11

Similar Documents

Publication Publication Date Title
MX2021013711A (es) Acido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin -3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilico para su uso en pacientes con cancer de mama metastasico o avanzado.
PH12020500091A1 (en) Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer
MXPA05012155A (es) Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades.
TW200500355A (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
IL244727A0 (en) Methods and preparations using immunomodulatory compounds for the treatment and management of cancer and other diseases
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
EP4327877A3 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2023006020A (es) Combinacion que comprende abemaciclib y acido 6-(2,4-diclorofenil)-5-[4-[(3s)- 1-(3-fluoropropil)pirrolidin-3-il ]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilico.
MX2009009574A (es) Tratamiento de melanoma.
TNSN07294A1 (en) Treatment of metastasized tumors
ZA202401684B (en) Novel parp7 inhibitor and use thereof
PH12022550790A1 (en) Oral complement factor d inhibitors
PH12021552513A1 (en) Pyrrole compounds
MX2026001199A (es) Inhibidores del factor d del complemento para administracion oral
MX2023013715A (es) Regímenes de dosis de ecubectedina.
MA42301B1 (fr) Sel cristallin de fumarate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl)azétidin-1-yl]-méthanone
MX2021015447A (es) Métodos de tratamiento del cáncer dirigidos a tumores fríos.
MX2022008342A (es) Metodos para tratar afecciones relacionadas con el receptor de s1p1.
IL185410A0 (en) Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione in the treatment of parkinson's disease
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
EP4585269A3 (en) Methods for cancer therapy
MX2022006083A (es) Metodos para tratar afecciones relacionadas con el receptor s1p1.
NZ587941A (en) Methods to inhibit tumor cell growth by using lansoprazole
ZA202400679B (en) Dimethyl-substituted thiazololactam compound and use thereof
WO2021015294A3 (en) Combination therapy for cancer treatment